Steve Helmke1, Jordi Colmenero, Gregory T Everson. 1. aUniversity of Colorado Denver School of Medicine, Aurora, Colorado, USA bLiver Unit, Biomedical Research Institute August Pi I Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain.
Abstract
PURPOSE OF REVIEW: It is our opinion that there is an unmet need in hepatology for a minimally or noninvasive test of liver function and physiology. Quantitative liver function tests define the severity and prognosis of liver disease by measuring the clearance of substrates whose uptake or metabolism is dependent upon liver perfusion or hepatocyte function. Substrates with high-affinity hepatic transporters exhibit high 'first-pass' hepatic extraction and their clearance measures hepatic perfusion. In contrast, substrates metabolized by the liver have low first-pass extraction and their clearance measures specific drug metabolizing pathways. RECENT FINDINGS: We highlight one quantitative liver function test, the dual cholate test, and introduce the concept of a disease severity index linked to clinical outcome that quantifies the simultaneous processes of hepatocyte uptake, clearance from the systemic circulation, clearance from the portal circulation, and portal-systemic shunting. SUMMARY: It is our opinion that dual cholate is a relevant test for defining disease severity, monitoring the natural course of disease progression, and quantifying the response to therapy.
PURPOSE OF REVIEW: It is our opinion that there is an unmet need in hepatology for a minimally or noninvasive test of liver function and physiology. Quantitative liver function tests define the severity and prognosis of liver disease by measuring the clearance of substrates whose uptake or metabolism is dependent upon liver perfusion or hepatocyte function. Substrates with high-affinity hepatic transporters exhibit high 'first-pass' hepatic extraction and their clearance measures hepatic perfusion. In contrast, substrates metabolized by the liver have low first-pass extraction and their clearance measures specific drug metabolizing pathways. RECENT FINDINGS: We highlight one quantitative liver function test, the dual cholate test, and introduce the concept of a disease severity index linked to clinical outcome that quantifies the simultaneous processes of hepatocyte uptake, clearance from the systemic circulation, clearance from the portal circulation, and portal-systemic shunting. SUMMARY: It is our opinion that dual cholate is a relevant test for defining disease severity, monitoring the natural course of disease progression, and quantifying the response to therapy.
Authors: G T Everson; M L Shiffman; J C Hoefs; T R Morgan; R K Sterling; D A Wagner; J L Desanto; T M Curto; E C Wright Journal: Aliment Pharmacol Ther Date: 2008-12-01 Impact factor: 8.171
Authors: Eric Levesque; Faouzi Saliba; Sonia Benhamida; Philippe Ichaï; Daniel Azoulay; René Adam; Denis Castaing; Didier Samuel Journal: Liver Transpl Date: 2009-10 Impact factor: 5.799
Authors: Alexander Lemmer; Lisa VanWagner; Zaira Gasanova; Steve Helmke; Gregory T Everson; Daniel Ganger Journal: Congenit Heart Dis Date: 2019-08-01 Impact factor: 2.007
Authors: Amanda Wieland; Ohad Etzion; Rabab O Ali; Elliot Levy; David E Kleiner; Steve M Helmke; Theo Heller; Gregory T Everson Journal: Clin Gastroenterol Hepatol Date: 2021-04-22 Impact factor: 11.382
Authors: Natasha McDonald; David M L Lilburn; Neil J Lachlan; Gillian Macnaught; Dilip Patel; Arjun N A Jayaswal; Peter C Hayes; Scott I Semple; Jonathan A Fallowfield Journal: Biomed Res Int Date: 2017-06-15 Impact factor: 3.411